NO20085385L - Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav - Google Patents

Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav

Info

Publication number
NO20085385L
NO20085385L NO20085385A NO20085385A NO20085385L NO 20085385 L NO20085385 L NO 20085385L NO 20085385 A NO20085385 A NO 20085385A NO 20085385 A NO20085385 A NO 20085385A NO 20085385 L NO20085385 L NO 20085385L
Authority
NO
Norway
Prior art keywords
compounds
receptor ligands
cannabinoid receptor
thiazole compounds
compositions
Prior art date
Application number
NO20085385A
Other languages
English (en)
Norwegian (no)
Inventor
Keith B Ryther
Teodozyj Kolasa
Meena V Patel
Michael J Dart
William A Carroll
Alan S Florjancic
Jennifer M Frost
Megan E Gallagher
Tongmei Li
Derek W Nelson
Sridhar Peddi
Arturo Perez-Medrano
Karin Rosemarie Tietje
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO20085385L publication Critical patent/NO20085385L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/14—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20085385A 2006-05-31 2008-12-29 Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav NO20085385L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80971206P 2006-05-31 2006-05-31
PCT/US2007/069921 WO2007140385A2 (fr) 2006-05-31 2007-05-30 Nouveaux composés en tant que ligands des récepteurs des cannabinoïdes et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
NO20085385L true NO20085385L (no) 2008-12-29

Family

ID=38662957

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085385A NO20085385L (no) 2006-05-31 2008-12-29 Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav

Country Status (17)

Country Link
US (1) US8546583B2 (fr)
EP (1) EP2038266A2 (fr)
JP (1) JP2009538931A (fr)
KR (1) KR20090018685A (fr)
CN (2) CN101454302A (fr)
AU (1) AU2007266535A1 (fr)
BR (1) BRPI0712720A2 (fr)
CA (1) CA2647597A1 (fr)
CR (1) CR10473A (fr)
DO (1) DOP2008000060A (fr)
EC (1) ECSP089020A (fr)
IL (1) IL194368A0 (fr)
MX (1) MX2008015217A (fr)
NO (1) NO20085385L (fr)
RU (1) RU2008152788A (fr)
TW (1) TW200804320A (fr)
WO (1) WO2007140385A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
WO2007140439A2 (fr) 2006-05-31 2007-12-06 Abbott Laboratories Nouveaux composés constituant des ligands de récepteurs cannabinoïdes et utilisations de ces composés
CN101454302A (zh) 2006-05-31 2009-06-10 艾博特公司 用作大麻素受体配位体的噻唑化合物及其用途
CA2657247A1 (fr) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Composes modulant le recepteur cb2
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008079687A1 (fr) * 2006-12-22 2008-07-03 Abbott Laboratories Nouveaux composés en tant que ligands du récepteur cannabinoïde et utilisations de ceux-ci
JP2010522760A (ja) 2007-03-28 2010-07-08 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての１，３−チアゾール−２（３ｈ）−イリデン化合物
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
MX2009012374A (es) * 2007-05-18 2009-12-01 Abbott Lab Compuestos novedosos como ligandos del receptor de canabinoides.
RU2354647C2 (ru) * 2007-06-28 2009-05-10 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе
RU2353619C2 (ru) * 2007-06-28 2009-04-27 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
CA2704684A1 (fr) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Composes modulant le recepteur cb2
WO2009067613A1 (fr) * 2007-11-21 2009-05-28 Abbott Laboratories Nouveaux composés en tant que ligands de récepteur de cannabinoïde et leurs utilisations
US8957063B2 (en) 2008-02-21 2015-02-17 Boehringer Ingelheim International Gmbh Amine and ether compounds which modulate the CB2 receptor
TW200942535A (en) 2008-03-11 2009-10-16 Abbott Lab Novel compounds as cannabinoid receptor ligands
US8178568B2 (en) 2008-07-10 2012-05-15 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the CB2 receptor
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
TW201016692A (en) 2008-09-16 2010-05-01 Abbott Lab Novel compounds as cannabinoid receptor ligands
CA2737639A1 (fr) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Composes modulant selectivement le recepteur cb2
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
US8629157B2 (en) 2009-01-05 2014-01-14 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the CB2 receptor
JP5705748B2 (ja) 2009-02-18 2015-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する複素環化合物
NZ596538A (en) 2009-05-12 2014-04-30 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
CN108042535A (zh) 2009-06-26 2018-05-18 罗马克实验室有限公司 用于治疗流感的化合物和方法
WO2011037795A1 (fr) 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Composés à modulation sélective du récepteur cb2
US8816086B2 (en) * 2009-12-16 2014-08-26 Abbvie Inc. Process for preparing cannabinoid receptor ligands
WO2011088015A1 (fr) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Composés qui modulent le récepteur cb2
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2012012307A1 (fr) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Composés sulfonylés qui modulent le récepteur cb2
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2014052831A1 (fr) * 2012-09-28 2014-04-03 Xavier University Of Louisiana Analogues du thiazole antimigration et anti-invasion pour le traitement d'une maladie proliférative cellulaire
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
BR112021004527A2 (pt) * 2018-09-14 2021-06-08 Spectrum Pharmaceuticals, Inc. kits e métodos para tratamento contra câncer
CN111548263A (zh) * 2020-05-26 2020-08-18 江苏巨莱生物医药有限公司 一种用于制备邻乙氧基苯甲酰氯的工艺方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3533331A1 (de) 1985-09-18 1987-03-26 Heumann Ludwig & Co Gmbh Pyridothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW205041B (fr) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
US6559186B1 (en) * 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
DE69319956T2 (de) * 1992-04-30 1999-01-14 Hodogaya Chemical Co., Ltd., Tokio/Tokyo Benzothiazolederivate und diese enthaltende fungizide Zusammensetzungen für Landwirtschaft und Gartenbau
US5654322A (en) * 1992-08-11 1997-08-05 Wakunaga Seiyaku Kabushiki Kaisha Biphenylmethane derivatives and pharmaceuticals containing the same
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
WO1998042703A1 (fr) * 1997-03-24 1998-10-01 Basf Aktiengesellschaft Derives de thiazolimine
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
FR2796643B1 (fr) * 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
CN1247553C (zh) * 1999-09-14 2006-03-29 盐野义制药株式会社 2－亚氨基－1,3－噻嗪衍生物
WO2003057693A1 (fr) * 2001-12-28 2003-07-17 Sumitomo Pharmaceuticals Co., Ltd. Composes cycliques a 5 chainons
ES2270080T3 (es) * 2002-05-16 2007-04-01 Bayer Cropscience Gmbh Derivados de piridincarboxamida pesticidas.
WO2005058887A1 (fr) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Nouveaux derives de thiazole
WO2005099353A2 (fr) 2004-04-19 2005-10-27 Symed Labs Limited Nouveau procede pour preparer du linezolide et des composes associes
WO2006008754A1 (fr) 2004-07-20 2006-01-26 Symed Labs Limited Nouveaux intermediaires pour linezolide et composes correspondants
JP2008514702A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
WO2006051704A1 (fr) 2004-11-15 2006-05-18 Taisho Pharmaceutical Co., Ltd. Composé imine
TW200700387A (en) 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) * 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
EP1951678A1 (fr) * 2005-10-21 2008-08-06 Mitsubishi Tanabe Pharma Corporation Composes pyrazole presentant une activite antagoniste du recepteur cannabinoide (cb1)
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
CN101454302A (zh) 2006-05-31 2009-06-10 艾博特公司 用作大麻素受体配位体的噻唑化合物及其用途
WO2007140439A2 (fr) 2006-05-31 2007-12-06 Abbott Laboratories Nouveaux composés constituant des ligands de récepteurs cannabinoïdes et utilisations de ces composés
CA2659762A1 (fr) * 2006-06-27 2008-01-03 Abbott Laboratories Derives de thiazoline et d'oxazoline et leurs procedes d'utilisation
US8796267B2 (en) * 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008079687A1 (fr) 2006-12-22 2008-07-03 Abbott Laboratories Nouveaux composés en tant que ligands du récepteur cannabinoïde et utilisations de ceux-ci
KR101222412B1 (ko) * 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
JP2010522760A (ja) * 2007-03-28 2010-07-08 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての１，３−チアゾール−２（３ｈ）−イリデン化合物
US7872033B2 (en) * 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
AU2008242703B2 (en) * 2007-04-19 2011-08-18 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
MX2009012374A (es) 2007-05-18 2009-12-01 Abbott Lab Compuestos novedosos como ligandos del receptor de canabinoides.
US7531685B2 (en) * 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (fr) * 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Pirfénidone déutérée
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) * 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
WO2009045476A1 (fr) * 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Dérivés de pyrimidinedione
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2009051782A1 (fr) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Étravirine deutérée
US20090105338A1 (en) * 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2217548A1 (fr) * 2007-10-26 2010-08-18 Concert Pharmaceuticals Inc. Darunavir deutere
WO2009067613A1 (fr) 2007-11-21 2009-05-28 Abbott Laboratories Nouveaux composés en tant que ligands de récepteur de cannabinoïde et leurs utilisations
TW200942535A (en) 2008-03-11 2009-10-16 Abbott Lab Novel compounds as cannabinoid receptor ligands
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
TW201016692A (en) * 2008-09-16 2010-05-01 Abbott Lab Novel compounds as cannabinoid receptor ligands
PA8854001A1 (es) * 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides

Also Published As

Publication number Publication date
IL194368A0 (en) 2009-08-03
EP2038266A2 (fr) 2009-03-25
ECSP089020A (es) 2009-01-30
US20080058335A1 (en) 2008-03-06
AU2007266535A1 (en) 2007-12-06
TW200804320A (en) 2008-01-16
CN101454302A (zh) 2009-06-10
MX2008015217A (es) 2008-12-12
JP2009538931A (ja) 2009-11-12
CR10473A (es) 2009-01-12
WO2007140385A2 (fr) 2007-12-06
RU2008152788A (ru) 2010-07-10
KR20090018685A (ko) 2009-02-20
DOP2008000060A (es) 2009-01-15
WO2007140385A3 (fr) 2008-02-07
US8546583B2 (en) 2013-10-01
CA2647597A1 (fr) 2007-12-06
BRPI0712720A2 (pt) 2012-11-20
CN102442970A (zh) 2012-05-09

Similar Documents

Publication Publication Date Title
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
WO2007140439A3 (fr) Nouveaux composés constituant des ligands de récepteurs cannabinoïdes et utilisations de ces composés
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
WO2007103550A3 (fr) Derives d'aminothiazole substitues presentant une activite anti-hcv
TW200833675A (en) Nicotinamide derivatives
NO20084278L (no) Bezothiazol derivatives as beta2 adrenoreceptor agonists
NO20081905L (no) Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
ATE530519T1 (de) Cyclobutylaminderivate
NO20074093L (no) Fremgangsmater for fremstilling av glukopyranosyl-substituerte benzyl-benzenderivater og mellomprodukter derav
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20075626L (no) Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
NO20081217L (no) Nye benzotiazolonderivater
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20084005L (no) Aminderivater
NO20083434L (no) Benzamid- og heteroarenderivater
WO2008040649A3 (fr) Dérivés de pyrazine-2-carboxamide
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application